The anti-TACI–anti-BCMA bispecific CAR T cells showed faster kinetics in reducing tumor burden (for example, at Day 10), though by Day 18 there were no significant differences among the treatment groups. This evidence concerns the gene TNFRSF17 and neoplasm.